BCS vs BRK-B
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
Barclays PLC (BCS) exhibits weak financial health with a Piotroski F-Score of just 2/9, indicating significant fundamental deterioration. Despite strong recent price performance and a low forward P/E of 8.96, the stock trades above both the Graham Number ($17.26) and intrinsic value estimate ($15.26), suggesting overvaluation. Profitability margins are strong, but ROA is extremely low at 0.44%, and earnings growth is negative both year-over-year and quarter-over-quarter. Combined with bearish insider activity and weak technical trend scores, the risk-reward profile is unattractive.
The deterministic health profile is weak, highlighted by a Piotroski F-Score of 3/9, indicating deteriorating operational efficiency and profitability trends. While the company maintains a fortress balance sheet with a Debt/Equity ratio of 0.19 and a Current Ratio of 7.07, the stock is trading at a significant premium to its growth-based intrinsic value of $217.21. Negative YoY revenue and earnings growth, coupled with a bearish technical trend, offset the positive analyst sentiment and long-term historical performance.
Compare Another Pair
Related Comparisons
BCS vs BRK-B: Head-to-Head Comparison
This page compares Barclays PLC (BCS) and Berkshire Hathaway Inc. (BRK-B) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.